Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.
Researchers found a microRNA signature in urine that can predict the presence of bladder cancer, advancing the idea of a noninvasive diagnostic test.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Researchers clarified the role of miR-125a-5p in bladder cancer, showing that it inhibits bladder cancer progression by targeting oncogene FUT4.
A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.
Treatment with NAC did not transform the prevailing subtype in bladder cancer — instead, shifts in cancer subtype were attributed to tumor plasticity.
Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.
Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder CancerSeptember 21, 2018
BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.
Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.
Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
A reanalysis suggested that an instillation of chemotherapy immediately after surgery may benefit all patients with non-muscle-invasive bladder cancer.
Patients in the SEER-Medicare database with stage IV bladder cancer were found to be less likely to receive chemotherapy than similar cohorts in earlier studies.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
With the advent of minimally invasive surgery programs, robotic-assisted radical cystectomy is becoming a point of interest for bladder cancer.
A better understanding of the factors associated with locoregional recurrence and focused adjuvant therapeutic strategies may lead to enhanced oncologic outcomes.
Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.
Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?